×
About 9,785 results

ALLMedicine™ Cutaneous Melanoma Center

Research & Reviews  4,737 results

Hypoxia-dependent drivers of melanoma progression.
https://doi.org/10.1186/s13046-021-01926-6 10.1002/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G 10.1111/apm.12529 10.1111/imm.12380 10.1158/0008-5472.CAN-03-2089 10.1007/s00018-011-0679-5 10.2174/1566524018666181109121849 10.1186/s13046-020-01544-8 10.1001/jamadermatol.2020.0470 10.1016/j.ejca.2004.10.016 10.1097/CMR.0000000000000686 10.1038/onc.2009.320 10.1097/00008390-199710000-00006 10.1016/j.cell.2008.02.038 10.1038/nature03664 10.1038/nature10539 10.1083/jcb.200501067 10.1158/0008-5472.CAN-06-3312 10.1172/JCI36157 10.1016/j.ejca.2010.01.031 10.1097/CMR.0000000000000393 10.1096/fasebj.13.1.9 10.1111/j.1365-2133.2010.10200.x 10.21873/anticanres.12806 10.1096/fj.02-0122fje 10.1038/cdd.2010.175 10.1016/S0002-9440(10)65173-5 10.1016/j.ejca.2013.07.148 10.1096/fj.201900786R 10.1038/labinvest.2009.20 10.1016/j.canlet.2006.08.016 10.1093/carcin/bgu018 10.1016/j.freeradbiomed.2011.05.042 10.1038/ncb1691 10.1002/biof.1499 10.1038/jid.2013.115 10.1016/j.ejca.2008.10.012 10.1006/excr.1999.4804 10.3892/or.2015.4449 10.1074/jbc.M308938200 10.2174/15665240113136660077 10.1038/s41388-020-1287-3 10.1002/jcp.20413 10.1172/JCI66715 10.1074/mcp.M112.020727 10.1016/j.ajpath.2011.08.038 10.4149/neo_2018_180828N655 10.4049/jimmunol.1103817 10.1158/2326-6066.CIR-18-0657 10.3892/mmr.2016.4888 10.3390/cancers12103018 10.1128/MCB.01395-06 10.18632/oncotarget.3142 10.3892/mmr.2016.5202 10.3892/etm.2017.4702 10.3892/etm.2016.3220 10.1080/15384047.2015.1030545 10.4161/auto.7.8.15598 10.1158/0008-5472.CAN-11-1094 10.1097/CMR.0b013e328346612c 10.1111/j.1755-148X.2009.00553.x 10.1016/j.prp.2013.07.004 10.1158/1535-7163.MCT-15-0963 10.1084/jem.20131916 10.1038/onc.2011.365 10.1038/mt.2008.266 10.2174/1573406412666160307151904 10.1039/C4NP00130C 10.1002/ptr.6273 10.18632/oncotarget.12108 10.4161/15384101.2015.941760 10.3892/ijo.2014.2397 10.1016/j.canlet.2009.04.030 10.1016/j.mvr.2018.10.008 10.1111/j.1755-148X.2012.01036.x 10.1158/1078-0432.CCR-20-0446 10.1097/CJI.0b013e31821dcefd 10.1002/cncr.31072 10.1016/j.ejca.2014.03.289 10.1007/s00280-018-3624-6 10.1097/00008390-200402000-00009 10.1002/cncr.24739 10.1159/000219435 10.1097/CMR.0b013e32833faf18 10.1007/s10637-013-9966-3 10.1046/j.0022-202X.2004.22231.x 10.1634/theoncologist.2015-0108 10.1038/sj.bjc.6602529 10.1001/jama.2011.746 10.1038/sj.bjc.6604482 10.1093/annonc/mdx079 10.1158/1078-0432.CCR-11-1987 10.1158/1078-0432.CCR-11-0534 10.1038/bjc.2014.541 10.1038/mt.2013.79 10.1158/1078-0432.CCR-11-2488 10.1007/s00280-014-2479-8 10.1158/1078-0432.CCR-11-1463 10.1097/IAE.0b013e31824d09a8 10.1007/s10555-017-9663-3 10.1016/j.ajhg.2016.09.008 10.1038/nature07586 10.1056/NEJMoa1000584 10.1001/jamaophthalmol.2013.129 10.1016/S0161-6420(98)92205-9 10.1177/112067219600600423 10.1002/cncr.20866 10.1016/j.ophtha.2011.01.040 10.1016/j.ejca.2011.10.004 10.1016/j.ophtha.2012.01.048 10.2147/OPTH.S113623 10.1159/000480640 10.1016/j.ajo.2005.05.034 10.1562/2006-07-17-RA-970 10.1038/eye.2015.51 10.1097/00004397-199303330-00012 10.1001/archophthalmol.2009.208 10.1016/j.ophtha.2013.03.012 10.1016/j.jcjo.2012.03.038 10.1167/iovs.14-15571 10.3322/caac.21388 10.1167/iovs.13-12195 10.1001/archopht.124.12.1684 10.1167/iovs.03-0538 10.1634/theoncologist.2015-0522 10.1016/j.ajo.2015.06.017 10.1001/archopht.1996.01100130743022 10.1016/0002-9394(85)90621-X 10.1016/j.ccell.2017.07.003 10.1158/1078-0432.CCR-18-1368 10.1167/iovs.09-4739 10.1007/s10585-006-9024-z 10.1007/s10585-011-9424-6 10.1097/CMR.0b013e3283005270 10.1097/00008390-199910000-00003 10.18632/oncotarget.6868 10.1167/iovs.12-10209 10.12659/MSM.917099 10.1097/00008390-199706000-00008 10.1016/S0161-6420(93)31470-3 10.1159/000329591 10.3109/02713683.2010.534573 10.3892/mco.2014.247 10.1001/jamaophthalmol.2014.43 10.1136/bjo.86.4.440 10.1007/s10637-013-0005-1 10.1097/MD.0000000000022091 10.1001/archopht.124.10.1428 10.1136/bjo.84.7.750 10.1038/bjc.1997.427 10.1167/iovs.12-10123 10.1073/pnas.131209798 10.1016/j.canlet.2020.09.013 10.1097/CMR.0b013e328336edfe 10.1038/modpathol.2011.63 10.2174/156652409788167131 10.1128/MCB.00166-09 10.1074/jbc.M800102200 10.1080/15548627.2019.1659614 10.1158/1078-0432.CCR-20-1675 10.1016/j.jconrel.2015.01.030 10.1111/j.1600-0749.2007.00363.x 10.1016/j.jaad.2009.01.018 10.18632/oncotarget.27431 10.18632/oncotarget.1379 10.1016/j.ejps.2018.08.002 10.1158/1078-0432.CCR-14-0489 10.1021/jm201018g 10.1167/iovs.09-3804 10.1007/s13277-015-4259-4 10.1167/iovs.13-12407 10.1097/CMR.0000000000000118 10.18632/oncotarget.25445 10.1016/j.bbrc.2018.05.069 10.3390/cancers11081056 10.1038/onc.2011.309 10.1167/iovs.09-4755 10.1007/s10637-012-9834-6 10.1016/j.ccr.2009.01.027 10.1212/WNL.0b013e318204a3af 10.1097/CMR.0b013e3283194118 10.1074/jbc.M403907200 10.1155/2011/210816 10.1158/1078-0432.CCR-17-1703 10.1080/02713680600865052 10.1358/mf.2005.27.3.890875 10.1089/jop.2005.21.107 10.1089/108076803322473015 10.1089/jop.2006.22.103 10.1007/s11060-011-0602-9 10.4161/cbt.11.2.13842 10.1097/CMR.0b013e32823ed0d1 10.1158/1078-0432.CCR-08-2243 10.1200/jco.2009.27.15_suppl.e20012 10.1097/CMR.0b013e328358b373 10.1200/jco.2013.31.15_suppl.9057 10.1038/bjc.2016.419 10.1200/JCO.2017.35.15_suppl.9511 10.1634/theoncologist.2015-0501 10.1038/bjc.2016.119 10.1038/bjc.2016.419 10.1158/1078-0432.CCR-19-1223 10.1097/CMR.0000000000000220 10.1016/j.oraloncology.2019.03.017 10.1002/cncr.29622 10.1002/cncr.30663 10.1200/JCO.2012.47.7836 10.1016/j.ejca.2019.07.010 10.1038/s41416-018-0207-6 10.1016/j.ejca.2019.11.016 10.1056/NEJMoa1003466 10.1097/IAE.0b013e31806e6042 10.1111/j.1755-3768.2007.00899.x 10.1001/jamaophthalmol.2019.5132 10.1111/ceo.13758 10.1016/j.oret.2019.02.009
Journal of Experimental & Clinical Cancer Research : CR; D'Aguanno S, Mallone F et. al.

May 9th, 2021 - Hypoxia, a condition of low oxygen availability, is a hallmark of tumour microenvironment and promotes cancer progression and resistance to therapy. Many studies reported the essential role of hypoxia in regulating invasiveness, angiogenesis, vasc...

Melanotransferrin is efficiently sorted on the surface of exosomes secreted by melanoma...
https://doi.org/10.1097/CMR.0000000000000741
Melanoma Research; Bonhoure A, Henry L et. al.

May 9th, 2021 - Cutaneous melanoma is the most lethal type of skin cancer. Early detection is crucial to improve the outcome of melanoma patients. The identification of noninvasive prognostic biomarkers for the follow-up of melanoma patients is still in demand fo...

Intratumour microbiome associated with the infiltration of cytotoxic CD8+ T cells and p...
https://doi.org/10.1016/j.ejca.2021.03.053
European Journal of Cancer (Oxford, England : 1990); Zhu G, Su H et. al.

May 7th, 2021 - The gut microbiome plays an important role in systemic inflammation and immune response. Microbes can translocate and reside in tumour niches. However, it is unclear how the intratumour microbiome affects immunity in human cancer. The purpose of t...

Expression of OPN3 in acral lentiginous melanoma and its associated with clinicohistopa...
https://doi.org/10.1002/iid3.438
Immunity, Inflammation and Disease; Zeng W, Zhang W et. al.

May 6th, 2021 - OPN3 upregulation associated with metastasis was recently described in two subtypes of lung cancers. And OPN3 identified in light-independent functions in epidermal melanocytes has already shown promise. However, in malignant melanocytic tissues, ...

see more →

Guidelines  29 results

Systemic Therapy for Melanoma: ASCO Guideline.
https://doi.org/10.1200/JCO.20.00198
Journal of Clinical Oncology : Official Journal of the Am... Seth R, Messersmith H et. al.

Apr 1st, 2020 - To provide guidance to clinicians regarding the use of systemic therapy for melanoma. ASCO convened an Expert Panel and conducted a systematic review of the literature. A systematic review, one meta-analysis, and 34 additional randomized trials we...

Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
https://jnccn.org/view/journals/jnccn/17/4/article-p367.xml

Mar 31st, 2019 - For adjuvant treatment of melanoma in patients rendered free of disease by surgery, traditional systemic therapy approaches have proven to be ineffective. Adjuvant interferon alfa (IFN alfa), particularly high-dose IFN alfa, has been widely used i...

Guidelines of care for the management of primary cutaneous melanoma.
https://doi.org/10.1016/j.jaad.2018.08.055
Journal of the American Academy of Dermatology; Swetter SM, Tsao H et. al.

Nov 5th, 2018 - The incidence of primary cutaneous melanoma continues to increase each year. Melanoma accounts for the majority of skin cancer-related deaths, but treatment is usually curative following early detection of disease. In this American Academy of Derm...

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immun...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5977556
Journal for Immunotherapy of Cancer; Sullivan RJ, Atkins MB et. al.

May 31st, 2018 - Cancer immunotherapy has been firmly established as a standard of care for patients with advanced and metastatic melanoma. Therapeutic outcomes in clinical trials have resulted in the approval of 11 new drugs and/or combination regimens for patien...

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunother...
https://jitc.biomedcentral.com/articles/10.1186/s40425-018-0362-6
Sullivan, R.

May 29th, 2018 - Cancer immunotherapy has been firmly established as a standard of care for patients with advanced and metastatic melanoma. Therapeutic outcomes in clinical trials have resulted in the approval of 11 new drugs and/or combination regimens for patien.

see more →

Drugs  1 results see all →

Clinicaltrials.gov  4,877 results

Hypoxia-dependent drivers of melanoma progression.
https://doi.org/10.1186/s13046-021-01926-6 10.1002/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G 10.1111/apm.12529 10.1111/imm.12380 10.1158/0008-5472.CAN-03-2089 10.1007/s00018-011-0679-5 10.2174/1566524018666181109121849 10.1186/s13046-020-01544-8 10.1001/jamadermatol.2020.0470 10.1016/j.ejca.2004.10.016 10.1097/CMR.0000000000000686 10.1038/onc.2009.320 10.1097/00008390-199710000-00006 10.1016/j.cell.2008.02.038 10.1038/nature03664 10.1038/nature10539 10.1083/jcb.200501067 10.1158/0008-5472.CAN-06-3312 10.1172/JCI36157 10.1016/j.ejca.2010.01.031 10.1097/CMR.0000000000000393 10.1096/fasebj.13.1.9 10.1111/j.1365-2133.2010.10200.x 10.21873/anticanres.12806 10.1096/fj.02-0122fje 10.1038/cdd.2010.175 10.1016/S0002-9440(10)65173-5 10.1016/j.ejca.2013.07.148 10.1096/fj.201900786R 10.1038/labinvest.2009.20 10.1016/j.canlet.2006.08.016 10.1093/carcin/bgu018 10.1016/j.freeradbiomed.2011.05.042 10.1038/ncb1691 10.1002/biof.1499 10.1038/jid.2013.115 10.1016/j.ejca.2008.10.012 10.1006/excr.1999.4804 10.3892/or.2015.4449 10.1074/jbc.M308938200 10.2174/15665240113136660077 10.1038/s41388-020-1287-3 10.1002/jcp.20413 10.1172/JCI66715 10.1074/mcp.M112.020727 10.1016/j.ajpath.2011.08.038 10.4149/neo_2018_180828N655 10.4049/jimmunol.1103817 10.1158/2326-6066.CIR-18-0657 10.3892/mmr.2016.4888 10.3390/cancers12103018 10.1128/MCB.01395-06 10.18632/oncotarget.3142 10.3892/mmr.2016.5202 10.3892/etm.2017.4702 10.3892/etm.2016.3220 10.1080/15384047.2015.1030545 10.4161/auto.7.8.15598 10.1158/0008-5472.CAN-11-1094 10.1097/CMR.0b013e328346612c 10.1111/j.1755-148X.2009.00553.x 10.1016/j.prp.2013.07.004 10.1158/1535-7163.MCT-15-0963 10.1084/jem.20131916 10.1038/onc.2011.365 10.1038/mt.2008.266 10.2174/1573406412666160307151904 10.1039/C4NP00130C 10.1002/ptr.6273 10.18632/oncotarget.12108 10.4161/15384101.2015.941760 10.3892/ijo.2014.2397 10.1016/j.canlet.2009.04.030 10.1016/j.mvr.2018.10.008 10.1111/j.1755-148X.2012.01036.x 10.1158/1078-0432.CCR-20-0446 10.1097/CJI.0b013e31821dcefd 10.1002/cncr.31072 10.1016/j.ejca.2014.03.289 10.1007/s00280-018-3624-6 10.1097/00008390-200402000-00009 10.1002/cncr.24739 10.1159/000219435 10.1097/CMR.0b013e32833faf18 10.1007/s10637-013-9966-3 10.1046/j.0022-202X.2004.22231.x 10.1634/theoncologist.2015-0108 10.1038/sj.bjc.6602529 10.1001/jama.2011.746 10.1038/sj.bjc.6604482 10.1093/annonc/mdx079 10.1158/1078-0432.CCR-11-1987 10.1158/1078-0432.CCR-11-0534 10.1038/bjc.2014.541 10.1038/mt.2013.79 10.1158/1078-0432.CCR-11-2488 10.1007/s00280-014-2479-8 10.1158/1078-0432.CCR-11-1463 10.1097/IAE.0b013e31824d09a8 10.1007/s10555-017-9663-3 10.1016/j.ajhg.2016.09.008 10.1038/nature07586 10.1056/NEJMoa1000584 10.1001/jamaophthalmol.2013.129 10.1016/S0161-6420(98)92205-9 10.1177/112067219600600423 10.1002/cncr.20866 10.1016/j.ophtha.2011.01.040 10.1016/j.ejca.2011.10.004 10.1016/j.ophtha.2012.01.048 10.2147/OPTH.S113623 10.1159/000480640 10.1016/j.ajo.2005.05.034 10.1562/2006-07-17-RA-970 10.1038/eye.2015.51 10.1097/00004397-199303330-00012 10.1001/archophthalmol.2009.208 10.1016/j.ophtha.2013.03.012 10.1016/j.jcjo.2012.03.038 10.1167/iovs.14-15571 10.3322/caac.21388 10.1167/iovs.13-12195 10.1001/archopht.124.12.1684 10.1167/iovs.03-0538 10.1634/theoncologist.2015-0522 10.1016/j.ajo.2015.06.017 10.1001/archopht.1996.01100130743022 10.1016/0002-9394(85)90621-X 10.1016/j.ccell.2017.07.003 10.1158/1078-0432.CCR-18-1368 10.1167/iovs.09-4739 10.1007/s10585-006-9024-z 10.1007/s10585-011-9424-6 10.1097/CMR.0b013e3283005270 10.1097/00008390-199910000-00003 10.18632/oncotarget.6868 10.1167/iovs.12-10209 10.12659/MSM.917099 10.1097/00008390-199706000-00008 10.1016/S0161-6420(93)31470-3 10.1159/000329591 10.3109/02713683.2010.534573 10.3892/mco.2014.247 10.1001/jamaophthalmol.2014.43 10.1136/bjo.86.4.440 10.1007/s10637-013-0005-1 10.1097/MD.0000000000022091 10.1001/archopht.124.10.1428 10.1136/bjo.84.7.750 10.1038/bjc.1997.427 10.1167/iovs.12-10123 10.1073/pnas.131209798 10.1016/j.canlet.2020.09.013 10.1097/CMR.0b013e328336edfe 10.1038/modpathol.2011.63 10.2174/156652409788167131 10.1128/MCB.00166-09 10.1074/jbc.M800102200 10.1080/15548627.2019.1659614 10.1158/1078-0432.CCR-20-1675 10.1016/j.jconrel.2015.01.030 10.1111/j.1600-0749.2007.00363.x 10.1016/j.jaad.2009.01.018 10.18632/oncotarget.27431 10.18632/oncotarget.1379 10.1016/j.ejps.2018.08.002 10.1158/1078-0432.CCR-14-0489 10.1021/jm201018g 10.1167/iovs.09-3804 10.1007/s13277-015-4259-4 10.1167/iovs.13-12407 10.1097/CMR.0000000000000118 10.18632/oncotarget.25445 10.1016/j.bbrc.2018.05.069 10.3390/cancers11081056 10.1038/onc.2011.309 10.1167/iovs.09-4755 10.1007/s10637-012-9834-6 10.1016/j.ccr.2009.01.027 10.1212/WNL.0b013e318204a3af 10.1097/CMR.0b013e3283194118 10.1074/jbc.M403907200 10.1155/2011/210816 10.1158/1078-0432.CCR-17-1703 10.1080/02713680600865052 10.1358/mf.2005.27.3.890875 10.1089/jop.2005.21.107 10.1089/108076803322473015 10.1089/jop.2006.22.103 10.1007/s11060-011-0602-9 10.4161/cbt.11.2.13842 10.1097/CMR.0b013e32823ed0d1 10.1158/1078-0432.CCR-08-2243 10.1200/jco.2009.27.15_suppl.e20012 10.1097/CMR.0b013e328358b373 10.1200/jco.2013.31.15_suppl.9057 10.1038/bjc.2016.419 10.1200/JCO.2017.35.15_suppl.9511 10.1634/theoncologist.2015-0501 10.1038/bjc.2016.119 10.1038/bjc.2016.419 10.1158/1078-0432.CCR-19-1223 10.1097/CMR.0000000000000220 10.1016/j.oraloncology.2019.03.017 10.1002/cncr.29622 10.1002/cncr.30663 10.1200/JCO.2012.47.7836 10.1016/j.ejca.2019.07.010 10.1038/s41416-018-0207-6 10.1016/j.ejca.2019.11.016 10.1056/NEJMoa1003466 10.1097/IAE.0b013e31806e6042 10.1111/j.1755-3768.2007.00899.x 10.1001/jamaophthalmol.2019.5132 10.1111/ceo.13758 10.1016/j.oret.2019.02.009
Journal of Experimental & Clinical Cancer Research : CR; D'Aguanno S, Mallone F et. al.

May 9th, 2021 - Hypoxia, a condition of low oxygen availability, is a hallmark of tumour microenvironment and promotes cancer progression and resistance to therapy. Many studies reported the essential role of hypoxia in regulating invasiveness, angiogenesis, vasc...

Melanotransferrin is efficiently sorted on the surface of exosomes secreted by melanoma...
https://doi.org/10.1097/CMR.0000000000000741
Melanoma Research; Bonhoure A, Henry L et. al.

May 9th, 2021 - Cutaneous melanoma is the most lethal type of skin cancer. Early detection is crucial to improve the outcome of melanoma patients. The identification of noninvasive prognostic biomarkers for the follow-up of melanoma patients is still in demand fo...

Study Finds Adjuvant Immunotherapy of Benefit to Patients With Stage IIB/C Melanoma
https://ascopost.com/issues/may-10-2021/adjuvant-immunotherapy-of-benefit-to-patients-with-stage-iibc-melanoma/

May 9th, 2021 - Radiation Therapy After Checkpoint Inhibition May Reduce Liver Metastases in Advanced Melanoma, Another Study Reports A significant survival advantage accrued to patients with stage IIB and IIC cutaneous melanoma who received adjuvant immunotherap...

Intratumour microbiome associated with the infiltration of cytotoxic CD8+ T cells and p...
https://doi.org/10.1016/j.ejca.2021.03.053
European Journal of Cancer (Oxford, England : 1990); Zhu G, Su H et. al.

May 7th, 2021 - The gut microbiome plays an important role in systemic inflammation and immune response. Microbes can translocate and reside in tumour niches. However, it is unclear how the intratumour microbiome affects immunity in human cancer. The purpose of t...

see more →

News  141 results

Mohs Surgery May Not Boost Survival Over Standard Excision of Melanomas on Trunk, Extremities
https://www.medscape.com/viewarticle/940003

Oct 29th, 2020 - NEW YORK (Reuters Health) - Compared with wide local excision (WLE), Mohs micrographic surgery (MMS) does not appear to increase overall survival in patients with trunk or extremity melanomas, according to a retrospective study. "In contrast to ou...

Melanoma Patients Still at Higher Risk for New Malignancy After Successful Systemic Immunotherapy
https://www.medscape.com/viewarticle/938007

Sep 24th, 2020 - NEW YORK (Reuters Health) - Patients successfully treated for metastatic melanoma with immune-checkpoint inhibitors remain at increased risk for developing new primary cutaneous melanoma, according to a new study. "The 5-year risk was nearly 5%," ...

Melanoma Patients Still at Higher Risk for New Malignancy After Successful Systemic Immunotherapy
https://www.staging.medscape.com/viewarticle/938007

Sep 24th, 2020 - NEW YORK (Reuters Health) - Patients successfully treated for metastatic melanoma with immune-checkpoint inhibitors remain at increased risk for developing new primary cutaneous melanoma, according to a new study. "The 5-year risk was nearly 5%," ...

Melanoma Experts Say 'No' to Routine Gene Profile Testing
https://www.medscape.com/viewarticle/936364

Aug 25th, 2020 - An international panel of 49 melanoma specialists has come out against routine gene expression profile (GEP) testing for cutaneous melanoma, pending solid proof of clinical benefit. "The currently published evidence is insufficient to establish th...

Fast Five Quiz: Malignant Melanoma
https://reference.medscape.com/viewarticle/936083_4

Aug 20th, 2020 - Four major clinicopathologic subtypes of primary cutaneous melanoma have been identified, although newer classifications of melanoma include location on chronically sun-exposed vs intermittently or non–sun-exposed skin and incorporate the presence...

see more →